-
Trichostatin A: An HO-1 Activity Assay Strategy
2026-08-13
Trichostatin A (TSA) can connect chromatin perturbation with direct HO-1 enzyme-activity measurements. This article explains how to combine HDAC inhibition, live-cell fluorescence, and orthogonal controls without confusing epigenetic changes with functional enzyme output.
-
CLCC1 and Herpesvirus Nuclear Egress Fusion
2026-08-13
The reference preprint identifies the host protein CLCC1 as an essential factor for the membrane-fusion step that releases herpes simplex virus 1 capsids from the nuclear envelope. By combining a whole-genome CRISPR screen with cellular and virological phenotyping, the study links herpesvirus nuclear egress to an ancient membrane organization process that also supports nuclear pore complex insertion.
-
BRD4–RAC1 Co-targeting in Breast Cancer
2026-08-12
The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, stem-like behavior, migration, and tumorigenesis. Its mechanistic contribution is the connection of this combination to the c-MYC–G9a–FTH1 axis and HDAC1-associated chromatin regulation, providing a framework for interpreting coordinated oncogenic and epigenetic dependencies.
-
SMPD4, Ceramide, and Brain Cilia Development
2026-08-12
The 2024 Development study identifies SMPD4-mediated ceramide production as a critical link between sphingolipid metabolism, primary cilia integrity, and brain development. By combining a mouse model with human SMPD4-deficient induced pluripotent stem cells, the authors connect ceramide deficiency to cerebellar hypoplasia, neural progenitor cell death, and shortened primary cilia.
-
Nullscript: An Assay-First HDAC Guide
2026-08-11
Nullscript is a histone deacetylase inhibitor designed for mechanistic studies that separate HDAC blockade from transcriptional facilitation. This assay-first guide connects its distinctive reporter profile with cardiac ischemia/reperfusion research and the pathway-validation lessons of recent necroptosis research.
-
IPR-803: Mechanism-to-Assay Guide
2026-08-11
IPR-803 is a urokinase receptor inhibitor designed to disrupt the uPAR–uPA interface rather than directly inhibit protease catalysis. This guide connects its structural rationale with assay selection, breast and pancreatic cancer models, and interpretation of invasion, angiogenesis, and metastasis data.
-
Reversine: Practical Aurora Kinase Inhibitor Workflow
2026-08-10
This guide explains how Reversine (SKU A3760) can be used to investigate Aurora kinase-dependent mitotic control, cancer cell proliferation inhibition, and apoptosis-related endpoints. It is intended for controlled laboratory research, not clinical, diagnostic, or therapeutic use, and the listed biochemical potencies should not be treated as universal cellular dosing instructions.
-
Dovitinib (TKI-258) Experimental Workflow Guide
2026-08-09
Dovitinib (TKI-258) enables researchers to connect broad RTK blockade with changes in ERK, STAT, proliferation, and apoptosis readouts. This workflow guide shows how to distinguish upstream target engagement from downstream cell-death effects across multiple myeloma, hepatocellular carcinoma, and immune-linked melanoma models.
-
CARMIL Membrane Binding and Actin Assembly
2026-08-08
A recent preprint defines multiple biochemical functions for the CARMIL membrane-binding domain, showing that it can both recruit capping protein to membranes and promote its release into a soluble, activation-competent state. The findings provide a mechanistic explanation for how CARMIL coordinates membrane targeting, barbed-end regulation, and Arp2/3-dependent actin assembly.
-
SCP4, H3T3 Dephosphorylation, and Chromosome Stability
2026-08-07
The reference study identifies SCP4 as a nuclear phosphatase that removes the mitotic H3T3 phosphate and helps position the chromosomal passenger complex on chromosomes. Its cellular and mouse-zygote evidence connects disrupted SCP4 activity with chromosome missegregation, lagging chromosomes, and aneuploidy, clarifying a previously unresolved layer of mitotic control.
-
CD40 and STING Competition Governs B Cell Activation in ESCC
2026-08-07
This study elucidates how the competitive binding of CD40 and STING with TRAF2 drives IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings highlight a novel mechanism linking TLS presence to favorable patient prognosis and open avenues for targeted immunotherapy strategies.
-
ER Stress Impairs Intestinal Stem Cells via GRP78/ATF6/CHOP
2026-08-06
This study demonstrates that endoplasmic reticulum (ER) stress, induced by tunicamycin, disrupts intestinal stem cell (ISC) maintenance and differentiation by activating the GRP78/ATF6/CHOP pathway and suppressing MAPK signaling. The findings clarify mechanisms linking ER stress to intestinal barrier dysfunction and provide insights for stem cell and cell cycle research.
-
Belinostat (PXD101): Optimizing HDAC Inhibition in Cancer Re
2026-08-06
Belinostat (PXD101) is a leading pan-HDAC inhibitor for dissecting epigenetic mechanisms in urothelial, prostate, and hepatocellular carcinoma models. This guide details robust workflows, troubleshooting, and insight-driven protocol refinements to maximize its impact across translational studies.
-
Etoposide (VP-16): DNA Double-Strand Breaks in Cancer Resear
2026-08-05
Etoposide (VP-16) is a potent DNA topoisomerase II inhibitor that induces DNA double-strand breaks, enabling precise apoptosis induction in cancer cell models. Its cytotoxicity and solubility parameters are well characterized, making it essential for DNA damage assays and cancer chemotherapy research. This article details its mechanism, evidence, and optimal workflow integration.
-
Optimizing Cell Proliferation with Murine Recombinant PDGF-B
2026-08-05
Murine recombinant PDGF-BB unlocks robust, reproducible cell proliferation assays for vascular remodeling and metabolic research. This guide distills advanced protocols, troubleshooting, and translational insights from pivotal pulmonary hypertension studies, empowering your workflow with evidence-backed strategies.